Immunogenic SARS-CoV-2 S and N Protein Peptide and Cytokine Combinations as Biomarkers for Early Prediction of Fatal COVID-19

• DOI: 10.3389/fimmu.2022.830715
• Publication Date: 2022-03-25T06:55:47Z
• Authors: Ekaterina Martynova; Shaimaa Hamza; Maria Markelova; Ekaterina Garanina; Yuriy Davidyuk; Venera Shakirova; Neha Kaushal; Manoj Baranwal; Robert J. Stott-M...; Toshana L. Foster; Albert Rizvanov; Svetlana Khaiboul...
• Keywords: Coronavirus

Early indications of the likelihood severe coronavirus disease 2019 COVID-19 can influence treatments and could improve clinical outcomes. However, knowledge on prediction markers fatality risks remains limited. Here, we analyzed quantified reactivity serum samples from acute (non-fatal fatal) convalescent patients with spike surface glycoprotein (S protein) nucleocapsid phosphoprotein (N SARS-CoV-2 peptide libraries. Cytokine activation was also analyzed. We demonstrated that IgM fatal reacted several N protein peptides. In contrast, non-fatal more S Further, higher levels pro-inflammatory cytokines were found in compared to non-fatal. Many these chemokines. Differences IgG sera demonstrated. Additionally, longitudinal analysis identified peptides highest longevity humoral immune response. Finally, using antibody selected cytokines, have a panel biomarkers specific risk who survive. This be used for early risk.